Tromsø, Norway - 30 April 2026 - ArcticZymes Technologies ASA (OSE: AZT), a
leading provider of specialised enzymes for advanced biomanufacturing and
molecular applications, today announced the grant of a new patent supporting
proprietary RNA restriction enzyme technologies for use within the therapeutic
RNA manufacturing workflow, supporting the Company's strategic expansion into
the rapidly growing RNA therapeutics manufacturing market.

The newly granted patent strengthens ArcticZymes' proprietary technology
platform with the introduction of a novel RNA restriction enzyme family focused
on enabling analytical, process development and manufacturing workflows for
therapeutic RNA production. The protection covers key application areas relevant
to RNA processing, quality control and scalable manufacturing workflows.

The global RNA therapeutics market continues to expand, driven by increasing
clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel
modalities. As programmes progress toward late-stage development and
commercialisation, demand is rising for robust, scalable and IP-secure
manufacturing technologies that can improve process efficiency, product quality
and regulatory confidence. ArcticZymes believes the newly granted patent
enhances its ability to participate in this market through differentiated
solutions that address critical workflow bottlenecks and support customers from
early development through commercial manufacturing.

"This patent grant represents an important milestone in the execution of our
long-term growth strategy," said Olav Lanes, VP of Scientific Strategy and
Technology at ArcticZymes Technologies. "We are building a strong intellectual
property foundation around innovative enzyme technologies for RNA therapeutics
manufacturing. Our new RNA restriction enzyme is designed to solve important
customer challenges across multiple workflow stages while creating long-term
commercial value."

The Company expects the protected technology to strengthen ongoing business
development discussions with prospective partners and customers active in RNA
therapeutics manufacturing.

ArcticZymes will continue investing in internal innovation, targeted IP creation
and strategic collaborations to expand its presence in high-growth
biomanufacturing segments.

"Strong intellectual property is essential in emerging therapeutics markets,"
said Michael Akoh, CEO of ArcticZymes Technologies. "Customers and partners
require long-term certainty, freedom to operate and trusted suppliers. This
patent further enhances our strategic position as we broaden ArcticZymes'
participation in RNA-based therapeutics manufacturing."

ArcticZymes believes RNA therapeutics represents a significant long-term growth
opportunity and remains committed to building a differentiated portfolio of
enabling technologies to serve this expanding market.

To be first to receive future announcements about ArcticZymes' new RNA enzyme
portfolio, click here (https://us21.list
-manage.com/survey?u=303693e6d24bfd4e8aeb444a8&id=396b6c1057&attribution=false)
to register your details.

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh          Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                    Tel +47 952 90187
                                     ir@arcticzymes.com

About ArcticZymes Technologies
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing, and commercialization of novel recombinant enzymes
for use in molecular research, in vitro diagnostics (IVD), and biomanufacturing.
The company has pioneered salt-active nucleases and continues to develop enzyme
solutions that support efficient and reliable production of advanced
therapeutics.